Results 181 to 190 of about 103,481 (331)

Action by intravenous injection of dopamine D2 agonist, talipexol and bromocriptine for the rat striatal neurons.

, 1994
Hiroaki Matsubayashi
openalex   +2 more sources

Adaptive Deep Brain Stimulation Benefits: Younger Patients with Persistent Wearing‐off Symptoms

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease (PD) often involves motor fluctuations and dyskinesia, which are difficult to manage with medication alone. Conventional deep brain stimulation (cDBS) effectively alleviates symptoms but has limitations, including the challenge of balancing therapeutic effects against potential side effects, as well as limited ...
Takuto Emura, Naoki Tani, Koichi Hosomi, Yuki Kimoto, Takahiro Matsuhashi, Takahiro Fujinaga, Shimpei Miura, Yuya Fujita, Nobuhiko Mori, Hui Ming Khoo, Satoru Oshino, Haruhiko Kishima   +11 more
wiley   +1 more source

Bivalent dopamine agonists with co-operative binding and functional activities at dopamine D2 receptors, modulate aggregation and toxicity of alpha synuclein protein. [PDF]

Bioorg Med Chem, 2023
Dinda B, Das B, Biswas S, Sharma H, Armstrong C, Yedlapudi D, Antonio T, Reith M, Dutta AK.   +8 more
europepmc   +1 more source

Effects of dopamine and alpha-2 adrenoceptor agonists and antagonists on ganglionic transmission in the cardiac sympathetic nerves of the dog.

, 1991
Osamu Mukaiyama, Tomohiko Kimura, Susumu Satoh   +2 more
openalex   +1 more source

Toward Understanding the Biology of a Complex Phenotype: Rat Strain and Substrain Differences in the Sensorimotor Gating-Disruptive Effects of Dopamine Agonists [PDF]

, 2000
Neal R. Swerdlow, Zoe Allen Martinez, Faith M. Hanlon, Amanda Platten, Marjan Farid, Pamela P. Auerbach, David Braff, Mark A. Geyer   +7 more
openalex   +1 more source

The Feasibility and Practical Utility of Virtual Visits for Patients with Parkinson's Disease in Different World Regions

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Overcoming existing access barriers is crucial for better‐specialized health care of patients with Parkinson's disease (PD). Objective The aim of the study was to compare the access and visit quality/acceptability between in‐office and virtual telemedicine visits.
Álvaro García‐Bustillo, Jinyoung Youn, Jong Hyeon Ahn, Oluwadamilola Ojo, Njideka Okubadejo, Zakiyah Aldaajani, Mohamed Essam, Ali Shalash, Adriana Cardozo, Meredith Spindler, Zoltan Mari, Esther Cubo   +11 more
wiley   +1 more source

Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis. [PDF]

Chin Neurosurg J, 2022
Cai X, Zhu J, Yang J, Tang C, Cong Z, Ma C.   +5 more
europepmc   +1 more source

Macroprolactinoma Shrinkage during Cabergoline Treatment Is Greater in Naive Patients Than in Patients Pretreated with Other Dopamine Agonists: A Prospective Study in 110 Patients1 [PDF]

, 2000
Annamaria Colao, Antonella Di Sarno, Maria Luisa Landi, Francesco Scavuzzo, Paolo Cappabianca, Rosario Pivonello, Raffaele Volpe, Francesco Di Salle, S. Cirillo, Lucio Annunziato, Gaetano Lombardi   +10 more
openalex   +1 more source

Othello Syndrome Induced by Dopamine Agonists in Parkinson's Disease: A Case Report. [PDF]

Case Rep Psychiatry
Ahmed GU, Ahmed HU, Raza AA, Samadi A.
europepmc   +1 more source

Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists. [PDF]

Front Endocrinol (Lausanne), 2021
Tang H, Cheng Y, Huang J, Li J, Zhang B, Wu ZB.   +5 more
europepmc   +1 more source